Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

KT430 is a preclinical, next-generation investigational gene therapy to treat X-linked myotubular myopathy (XLMTM) TOKYO and SAN DIEGO, June 8, 2023 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki ... Biopharmaceuticals, Regenerative Medicine, Licensing Astellas Pharma, Kate Therapeutics, X-linked myotubular myopathy, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news